Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma
Multicentric lymphoma is the most common type of hematopoietic neoplasm in dogs. Chemotherapeutic protocols typically consist of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). The 15- and 19-week CHOP protocols exhibit similar outcomes, indicating that a shorter treatment durat...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-02-01
|
| Series: | Animals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2615/15/4/522 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238883425419264 |
|---|---|
| author | Yi-Chen Lin Shang-Lin Wang |
| author_facet | Yi-Chen Lin Shang-Lin Wang |
| author_sort | Yi-Chen Lin |
| collection | DOAJ |
| description | Multicentric lymphoma is the most common type of hematopoietic neoplasm in dogs. Chemotherapeutic protocols typically consist of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). The 15- and 19-week CHOP protocols exhibit similar outcomes, indicating that a shorter treatment duration may be a feasible treatment option. However, the 19-week LHOP protocol, which uses L-asparaginase instead of cyclophosphamide, results in a longer progression-free survival and a similar survival time compared to CHOP-based chemotherapy regimens. In this study, we conducted and historically compared the efficacy of the 15- and 19-week LHOP protocols to determine whether there are any differences in efficacy. Eighteen and twenty dogs underwent the 15- and 19-week LHOP protocols, respectively. No significant differences were found in age, body weight, sex, clinical stage, substage, T-cell phenotype, hypercalcemia status, and overall response rate between the two groups. The time to progression (TTP) and lymphoma-specific survival (LSS) for the 19-week LHOP protocol were significantly longer than those for the 15-week LHOP protocol (<i>p</i> = 0.004 and <i>p</i> = 0.008, respectively). Thus, the 19-week LHOP protocol may be a better treatment option for dogs with multicentric lymphoma. However, the 15-week LHOP protocol lowered the treatment cost and reduced the treatment time. |
| format | Article |
| id | doaj-art-d0d8e0d6de3041bb860d11b423578d7e |
| institution | OA Journals |
| issn | 2076-2615 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Animals |
| spelling | doaj-art-d0d8e0d6de3041bb860d11b423578d7e2025-08-20T02:01:20ZengMDPI AGAnimals2076-26152025-02-0115452210.3390/ani15040522Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric LymphomaYi-Chen Lin0Shang-Lin Wang1Graduate Institute of Veterinary Clinical Sciences, School of Veterinary Medicine, National Taiwan University, Taipei 10617, TaiwanGraduate Institute of Veterinary Clinical Sciences, School of Veterinary Medicine, National Taiwan University, Taipei 10617, TaiwanMulticentric lymphoma is the most common type of hematopoietic neoplasm in dogs. Chemotherapeutic protocols typically consist of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). The 15- and 19-week CHOP protocols exhibit similar outcomes, indicating that a shorter treatment duration may be a feasible treatment option. However, the 19-week LHOP protocol, which uses L-asparaginase instead of cyclophosphamide, results in a longer progression-free survival and a similar survival time compared to CHOP-based chemotherapy regimens. In this study, we conducted and historically compared the efficacy of the 15- and 19-week LHOP protocols to determine whether there are any differences in efficacy. Eighteen and twenty dogs underwent the 15- and 19-week LHOP protocols, respectively. No significant differences were found in age, body weight, sex, clinical stage, substage, T-cell phenotype, hypercalcemia status, and overall response rate between the two groups. The time to progression (TTP) and lymphoma-specific survival (LSS) for the 19-week LHOP protocol were significantly longer than those for the 15-week LHOP protocol (<i>p</i> = 0.004 and <i>p</i> = 0.008, respectively). Thus, the 19-week LHOP protocol may be a better treatment option for dogs with multicentric lymphoma. However, the 15-week LHOP protocol lowered the treatment cost and reduced the treatment time.https://www.mdpi.com/2076-2615/15/4/522caninechemotherapyL-asparaginaseLymphomaoutcome |
| spellingShingle | Yi-Chen Lin Shang-Lin Wang Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma Animals canine chemotherapy L-asparaginase Lymphoma outcome |
| title | Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma |
| title_full | Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma |
| title_fullStr | Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma |
| title_full_unstemmed | Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma |
| title_short | Comparison of the Efficacy of 15- and 19-Week Chemotherapy Protocols Based on Vincristine, L-Asparaginase, Doxorubicin, and Prednisolone for Dogs with Multicentric Lymphoma |
| title_sort | comparison of the efficacy of 15 and 19 week chemotherapy protocols based on vincristine l asparaginase doxorubicin and prednisolone for dogs with multicentric lymphoma |
| topic | canine chemotherapy L-asparaginase Lymphoma outcome |
| url | https://www.mdpi.com/2076-2615/15/4/522 |
| work_keys_str_mv | AT yichenlin comparisonoftheefficacyof15and19weekchemotherapyprotocolsbasedonvincristinelasparaginasedoxorubicinandprednisolonefordogswithmulticentriclymphoma AT shanglinwang comparisonoftheefficacyof15and19weekchemotherapyprotocolsbasedonvincristinelasparaginasedoxorubicinandprednisolonefordogswithmulticentriclymphoma |